← Every company
BioCryst Pharmaceuticals Inc Executive Compensation
What BioCryst Pharmaceuticals Inc's board awarded its chief executive, and what the same award was worth once the share price had moved. Companies have had to disclose both since 2023, and they routinely differ by several times over.
BCRX on carbonthat →Latest year
2025
5 years disclosed
Awarded that year
$13M
Actually paid
$1.2M
after revaluation
Across every year
$40.1M
$29.5M actually paid
Year by year
Newest first. A negative figure means the award lost more than its whole value over the year.
| Year | Awarded | Actually paid |
|---|---|---|
| 20250.1×$100 → $105 | $13M | $1.2M |
| 20241.3×$100 → $101 | $8.3M | $11M |
| 2023-0.8×$100 → $80 | $4.8M | -$3.7M |
| 20220.6×$100 → $154 | $7M | $4M |
| 20212.4×$100 → $186 | $7.1M | $17.1M |
Source: pay-versus-performance disclosures, read from SEC XBRL company facts. "Compensation actually paid" is a revaluation of awards that may never vest, not cash received — a board that awards shares and watches them halve discloses the second, smaller figure, and that is the disclosure working rather than a pay cut. Only the years a company tagged where the SEC's data can reach them appear here.
More on BCRX
Company overviewEverything on BCRX in one place, with the price.SEC filingsWhat BCRX's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat BCRX's own officers and directors buy and sell.Who owns itEvery manager reporting a position in BCRX.Funds holding itWhich funds and ETFs hold BCRX, and how big a bet.Federal contractsWhat federal agencies pay BCRX.PatentsWhat BCRX is filing at the patent office.